Cylene Pharmaceuticals About UsProductsDevelopment ProgramsPress ReleasesCareers
A Product-focused oncology company
CLINICAL PROGRAMS
  • Quarfloxin is a novel Nucleolus Targeting Agents (NTA) that induces apoptotic cell death in tumor cells; the compound is in Phase II development for carcinoid/neuroendocrine tumors.

  • CX-4945 is a first-in-class oral CK2 protein kinase inhibitor that demonstrates broad spectrum anti-proliferative activity in cancer cell lines; the compound is in Phase I development for cancers driven by overexpression of CK2 (for example, breast and prostate cancers).

  • As Co-Founder and VP, Medical Affairs, Daniel Von Hoff, M.D., F.A.C.P. guides the clinical trials.
© 2010 Cylene Pharmaceuticals   | Terms of Use | Privacy Policy
CONTACT SITE MAP

built@zoomedia